Molecular Genetic Analysis of Colorectal Cancer

结直肠癌的分子遗传学分析

• 批准号: 7210182
• 负责人: Bert Vogelstein
• 金额: $ 43.89万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-08-01 至 2011-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7210182
• 关键词: AKT1 gene; Affect; Alleles; Baculovirus Expression System; Benzofurans; Binding; Biochemistry; Cancer Patient; Cancer cell line; Cell Line; Cells; Class; Clinical; Colorectal; Colorectal Cancer; Colorectal Neoplasms; Common Neoplasm; Complex; Condition; Dependence; Development; Diagnosis; Diagnostic; Disruption; Enzyme Inhibitor Drugs; Enzyme Inhibitors; Enzymes; FOXO1A gene; Frequencies; Future; Gene Expression Profile; Gene Targeting; Genes; Genetic; Genetic Transcription; Goals; Grant; Growth; Growth Factor; Hot Spot; Human; In Vitro; Knowledge; Laboratories; Lead; Light; Lipids; Malignant Neoplasms; Mediating; Methods; Microarray Analysis; Molecular; Molecular Genetics; Molecular Structure; Mutate; Mutation; Nature; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Neoplastic Processes; Oncogenes; PIK3CA gene; Pathogenesis; Pathway interactions; Phenotype; Phosphorylation; Phosphotransferases; Physiological; Physiology; Positioning Attribute; Process; Property; Protein Isoforms; Proteins; Public Health; Research; Research Personnel; Research Support; Risk Assessment; Role; Series; Specificity; Staging; Standards of Weights and Measures; Structure; System; Technology; Testing; Therapeutic; Tumor Cell Biology; Tumor Cell Invasion; Tumor Suppressor Genes; X-Ray Crystallography; benzofuran; benzothiophene; cancer cell; design; drug discovery; enzyme structure; experience; forkhead protein; gene discovery; genetic analysis; homologous recombination; human PIK3CA protein; improved; in vivo; inhibitor/antagonist; insight; interest; mutant; novel; outcome forecast; programs; serial analysis of gene expression; small molecule; transcription factor; tumor; tumor progression

DESCRIPTION (provided by applicant): During the past five years, we have discovered several novel genetic alterations in colorectal tumors that are central to its pathogenesis. The most interesting of these affected PIK3CA, a lipid kinase mutated in more than 30% of the tumors. The mutations were clustered in two hot-spots and were altered at similar frequencies and positions in several other common tumor types. The PIK3CA gene is therefore one of the two most highly mutated oncogenes ever identified in human cancers. Our future efforts will be devoted to its further exploration and will incorporate four major components: 1. We will use targeted homologous recombination to disrupt the genes that appear to mediate the biologic effects of PIK3CA in colorectal cancer cells. By comparison of the properties of these cells to those in which mutant or wild-type forms of PIK3CA have been disrupted, we will define the role of each gene in each phenotype associated with PIK3CA mutation. 2. We will determine the changes in transcription associated with PIK3CA mutation using SAGE and microarray technologies. Genes identified through the expression analyses will themselves be subject to targeted disruption to test their physiologic roles in colorectal cancer cells. 3. We will develop small molecular inhibitors of the p110a enzyme encoded by PIK3CA, preferably specific for the mutant form but at minimum specific for the a isoform. Cells in which PIK3CA pathway genes have been disrupted will provide unique tests of specificity of such compounds. 4. We will determine the molecular structure of wild-type and mutant forms of the PIK3CA gene product, both alone and in complex with small molecule inhibitors. Such structures will be used to guide drug discovery as well as to provide insights into the mechanisms through which PIK3CA mutations affect enzymatic function. Relevance to Public Health: These studies represent an integrated program of research that will illuminate key features of one of the most important pathways contributing to human neoplasia. It is likely to have substantial implications for the diagnosis and treatment of cancer patients.

描述（由申请人提供）：在过去的五年中，我们发现了几个新的遗传改变，在结直肠肿瘤是其发病机制的核心。其中最有趣的是影响PIK3CA，这是一种在超过30%的肿瘤中突变的脂质激酶。这些突变聚集在两个热点中，并且在其他几种常见肿瘤类型中以相似的频率和位置发生改变。因此，PIK3CA基因是人类癌症中发现的两种最高度突变的癌基因之一。我们今后的工作将致力于进一步的探索，并将包括四个主要组成部分：1。我们将使用靶向同源重组来破坏似乎介导PIK3CA在结直肠癌细胞中的生物学效应的基因。通过将这些细胞的性质与其中突变型或野生型形式的PIK3CA已被破坏的那些细胞的性质进行比较，我们将定义每个基因在与PIK3CA突变相关的每个表型中的作用。2.我们将使用SAGE和微阵列技术确定与PIK3CA突变相关的转录变化。通过表达分析鉴定的基因本身将受到靶向破坏，以测试它们在结直肠癌细胞中的生理作用。3.我们将开发PIK3CA编码的p110a酶的小分子抑制剂，优选对突变体形式具有特异性，但至少对a亚型具有特异性。其中PIK3CA途径基因已被破坏的细胞将提供此类化合物的特异性的独特测试。4.我们将确定PIK3CA基因产物的野生型和突变形式的分子结构，无论是单独的还是与小分子抑制剂复合的。这些结构将用于指导药物发现，并提供对PIK3CA突变影响酶功能的机制的见解。与公共卫生的相关性：这些研究代表了一个综合研究计划，将阐明导致人类肿瘤形成的最重要途径之一的关键特征。这可能对癌症患者的诊断和治疗有重大意义。